Next Article in Journal
Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
Next Article in Special Issue
Multivalent DNA Vaccines as a Strategy to Combat Multiple Concurrent Epidemics: Mosquito-Borne and Hemorrhagic Fever Viruses
Previous Article in Journal
Nudivirus Sequences Identified from the Southern and Western Corn Rootworms (Coleoptera: Chrysomelidae)
Previous Article in Special Issue
The Key Role of Nucleic Acid Vaccines for One Health

Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype

by 1,2
Department of Dermatology, University Hospital of Zürich, Gloriastrasse 31, 8091 Zürich, Switzerland
Faculty of Medicine, University of Zürich, 8091 Zürich, Switzerland
Academic Editors: B.A.M. (Ben) van der Zeijst and P.J.M. (Peter) Rottier
Received: 6 January 2021 / Revised: 2 February 2021 / Accepted: 4 February 2021 / Published: 9 February 2021
(This article belongs to the Special Issue Nucleic Acid Vaccines)
In the race for a vaccine against SARS-CoV-2, the synthetic mRNA format has been shown to be the fastest one and proved to be safe and highly efficient, even at the very low dose of a few µg per injection. The mRNA vaccines are not new: vaccines that are based on attenuated mRNA viruses, such as Mumps, Measles, and Rubella, immunize by delivering their mRNAs into the cells of the vaccinated individual, who produces the viral proteins that then prime the immune response. Synthetic mRNA in liposomes can be seen as a modern, more refined, and thereby a safer version of those live attenuated RNA viruses. The anti-COVID-19 mRNA vaccine (coding the SARS-CoV-2 spike protein) is the third synthetic RNA therapeutic being approved. It follows the aptamer Macugen® (which neutralizes VEGF) and the siRNA Onpattro® (which destroys the transthyretin-coding mRNA). Remarkably, the 30 µg of mRNA that are contained in the first approved anti-COVID-19 vaccine are sufficient for generating high levels of neutralizing antibodies against the virus in all injected volunteers (including participants over 65 years old). The efficacy and safety data are stunning. The distribution of these vaccines throughout the world will bring a halt to the coronavirus pandemic. View Full-Text
Keywords: mRNA; SARS-CoV-2; vaccine; spike protein mRNA; SARS-CoV-2; vaccine; spike protein
Show Figures

Figure 1

MDPI and ACS Style

Pascolo, S. Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype. Viruses 2021, 13, 270.

AMA Style

Pascolo S. Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype. Viruses. 2021; 13(2):270.

Chicago/Turabian Style

Pascolo, Steve. 2021. "Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype" Viruses 13, no. 2: 270.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop